Bortezomib Induced Peripheral Neuropathy: A Systematic Review of Phase III Trials
Bortezomib is a proteasome inhibitor commonly used for the treatment of multiple myeloma (MM). Its proven efficacy has resulted in increased survival rates in both the newly diagnosed and relapsed/refractory cohorts. Bortezomib-induced peripheral neuropathy (BIPN) is a disabling and common toxicity associated with this treatment, typically requiring dose reduction, delay or cessation of treatment protocol. It typically presents as numbness, tingling and paraesthesia manifesting in the peripheral domain in a glove and stocking distribution.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tiffany Li, Hannah Timmins, Tracy King, Matthew Kiernan, David Goldstein, Susanna Park Source Type: research
More News: Brain | Hematology | Leukemia | Lymphoma | Myeloma | Neurology | Peripheral Neuropathy | Toxicology | Velcade